Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT01861938
Other study ID # 0419-12-HMO
Secondary ID
Status Not yet recruiting
Phase Phase 2/Phase 3
First received December 20, 2012
Last updated May 23, 2013
Start date June 2013

Study information

Verified date December 2012
Source Hadassah Medical Organization
Contact n/a
Is FDA regulated No
Health authority Israel: Israel Ministry of Health
Study type Interventional

Clinical Trial Summary

This study is based on the hypothesis that stimulation of the immune response against the tumor can help destroy residual tumor in melanoma patients with very high risk for disease recurrence and in patients with relatively low tumor burden who already got first line treatment for their disease.

Ongoing clinical trials in the Hadassah Hospital have shown that vaccination of patients with a cell line of tumor cells from the patient himself, or with a combination of three cell lines that partially match the patient's cell characteristics, could improve the immune response against the tumor, was associated with improved disease-free and overall survival.

In this study, the investigators will evaluate the efficacy of a modified tumor cell vaccine, in terms of immune response,improved disease-free and overall survival. The vaccine consists of a cell line that has a high expression level of melanoma molecules, and has been genetically modified to induce a strong immune response.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

1. Patients included in this protocol must carry one or more of the following tissue typing alleles: HLA-A2, -A24, -A33, -B35, -B49, -CW04/12(04/08). We estimate that 50% of melanoma patients will be eligible.

2. Cutaneous malignant melanoma AJCC stage IIb (over 4 mm) or IIc (ulcerated melanoma over 4mm).

3. Metastatic melanoma AJCC stage III (nodal involvement, N1-3a,b) post surgical removal of lymph nodes.

4. Metastatic melanoma AJCC stage IV, completely resected.

5. Non cutaneous malignant melanoma of respective stages including uveal and mucosal melanoma.

6. Melanoma can be of either mutant or wild-type B-RAF.

7. Karnofsky performance status over 80 (Normal activity with effort).

8. No active cardio-respiratory disease.

9. Hematocrit over 25% and WBC over 3000.

10. Informed consent of the patient.

Exclusion Criteria:

1. Administration of cytotoxic drugs or extensive radiotherapy less than 28 days prior to protocol administration.

2. Active brain metastases requiring cortico-steroids.

3. Concurrent malignancy (other than skin cancer, carcinoma in situ of cervix and early stage prostate cancer).

4. Active serious infection.

5. Allergy to penicillin.

6. Patient's wish to withdraw from the study at any stage.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Biological:
Melanoma vaccine modified to express HLA A2/4-1BB ligand


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Hadassah Medical Organization

Outcome

Type Measure Description Time frame Safety issue
Other Emergence of anti-tumor T cell reactivity To be measured one month after the last vaccine was admininstered, on average 18-20 weeks after treatment start No
Primary Number of adverse effects For 20 weeks from the start of treatment Yes
Secondary Overall and disease free survival For at least five years No
See also
  Status Clinical Trial Phase
Terminated NCT01450683 - Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy Phase 2
Terminated NCT04116164 - Safety and Targeting of Anti-hk2 Antibody in mCRPC Early Phase 1
Completed NCT04595032 - MAnagement of METastatic Disease In Campania (MAMETIC)
Terminated NCT01020305 - Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer Phase 1/Phase 2
Withdrawn NCT02496832 - A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo N/A
Completed NCT01763970 - Stereotactic Radiation Therapy for Pediatric Sarcomas N/A
Completed NCT01703910 - Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic Phase 2
Completed NCT00609401 - Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC) Phase 2
Completed NCT02628379 - Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
Completed NCT00480389 - Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal Phase 2
Recruiting NCT03632005 - Negative Pressure Wound Therapy vs. Sterile Dressing for Patients Undergoing Thoracolumbar Spine Surgery N/A
Recruiting NCT04492735 - The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies
Terminated NCT02175654 - Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab Phase 2
Completed NCT01875380 - Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer Phase 2
Terminated NCT00532454 - Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen Phase 2
Terminated NCT02795819 - Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer Phase 1
Recruiting NCT05188911 - Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial
Completed NCT03823989 - Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients Phase 1
Terminated NCT01904916 - CPCT-05 Biopsy Protocol Patient Selection N/A
Terminated NCT01484860 - Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy Phase 2